Levonorgestrel-ethinyl estradiol combinations — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Contraception (Oral)

• Norethindrone-ethinyl estradiol various microgram combinations

About Levonorgestrel-ethinyl estradiol combinations

Levonorgestrel and ethinyl estradiol combinations are widely prescribed hormonal medications, primarily known for contraception but offering other health benefits. Navigating medication costs can be challenging, but with TheDrugClub, accessing this essential medication is simpler and more affordable. Levonorgestrel and ethinyl estradiol are synthetic hormones – a progestin and an estrogen, respectively – that work together in various combination birth control pills. These medications are a cornerstone of reproductive healthcare and offer several advantages beyond preventing pregnancy. ### What Levonorgestrel/Ethinyl Estradiol Treats

While primarily used as a highly effective form of contraception, levonorgestrel/ethinyl estradiol combinations are also prescribed to manage a range of other conditions. They can help regulate menstrual cycles, making periods lighter and more predictable. Many women find relief from severe menstrual cramps (dysmenorrhea) and symptoms of Premenstrual Dysphoric Disorder (PMDD). Additionally, these combinations are often used to improve acne by reducing androgen levels, which contribute to breakouts. In some cases, they may also be prescribed off-label for conditions like endometriosis to help manage pain and slow disease progression. ### How It Works

This medication works by mimicking the body's natural hormones, primarily to prevent ovulation (the release of an egg from the ovary). The ethinyl estradiol (estrogen) helps to stabilize the uterine lining, while the levonorgestrel (progestin) is the primary hormone responsible for preventing ovulation. Beyond stopping egg release, it also thickens cervical mucus, making it harder for sperm to reach an egg, and thins the uterine lining, making it less receptive to a fertilized egg if one were to implant. These multiple mechanisms of action contribute to its high efficacy as a contraceptive. ### Typical Costs and TheDrugClub Advantage

The typical cost of levonorgestrel/ethinyl estradiol combinations can vary significantly based on the brand, dosage, and whether you purchase a generic version. Without insurance, a monthly supply

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Levonorgestrel-ethinyl estradiol combinations is approved for (FDA label)

Levonorgestrel and ethinyl estradiol tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and implants, depend upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.

Source: Read the full FDA label on DailyMed. Label effective date: January 30, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Levonorgestrel-ethinyl estradiol combinations (FDA label)

Cigarette smoking increases the risk of serious adverse effects on the heart and blood vessels from oral contraceptive use. This risk increases with age and with the amount of smoking (15 or more cigarettes per day has been associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should not smoke.

Source: FDA prescribing information (DailyMed). Set ID: 44fbc5ae-5682-471f-a12a-955e8b4d233a. SPL document ID: ed921f2c-7961-477a-bbac-2e666d32e3ba. Label effective date: January 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Levonorgestrel-ethinyl estradiol combinations (FDA label)

An increased risk of the following serious adverse reactions (see WARNINGS section for additional information) has been associated with the use of oral contraceptives: Thromboembolic and thrombotic disorders and other vascular problems (including thrombophlebitis and venous thrombosis with or without pulmonary embolism, mesenteric thrombosis, arterial thromboembolism, myocardial infarction, cerebral hemorrhage, cerebral thrombosis, transient ischemic attack), carcinoma of the reproductive organs and breasts, hepatic neoplasia/liver disease (including hepatic adenomas or benign liver tumors), ocular lesions (including retinal vascular thrombosis), gallbladder disease, carbohydrate and lipid effects, elevated blood pressure, and headache including migraine.

Source: FDA prescribing information (DailyMed). Set ID: 44fbc5ae-5682-471f-a12a-955e8b4d233a. SPL document ID: ed921f2c-7961-477a-bbac-2e666d32e3ba. Label effective date: January 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Levonorgestrel-ethinyl estradiol combinations (FDA label)

Levonorgestrel and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions : Thrombophlebitis or thromboembolic disorders History of deep-vein thrombophlebitis or thromboembolic disorders Cerebrovascular or coronary artery disease (current or past history) Valvular heart disease with thrombogenic complications Thrombogenic rhythm disorders Hereditary or acquired thrombophilias Major surgery with prolonged immobilization Diabetes with vascular involvement Headaches with focal neurological symptoms such as aura Uncontrolled hypertension Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia Undiagnosed abnormal genital bleeding Cholestatic jaundice of pregnancy or jaundice with prior pill use Hepatic adenomas or carcinomas, or active liver disease Known or suspected pregnancy Hypersensitivity to any of the components of levonorgestrel and ethinyl estradiol.

Source: FDA prescribing information (DailyMed). Set ID: 44fbc5ae-5682-471f-a12a-955e8b4d233a. SPL document ID: ed921f2c-7961-477a-bbac-2e666d32e3ba. Label effective date: January 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Levonorgestrel-ethinyl estradiol combinations (FDA label)

Changes in Contraceptive Effectiveness Associated with Coadministration of Other Products: Contraceptive effectiveness may be reduced when hormonal contraceptives are coadministered with antibiotics, anticonvulsants, and other drugs that increase the metabolism of contraceptive steroids. This could result in unintended pregnancy or unscheduled bleeding. Examples include rifampin, rifabutin, barbiturates, primidone, phenylbutazone, phenytoin, dexamethasone, carbamazepine, felbamate, oxcarbazepine, topiramate, griseofulvin, and modafinil. In such cases a nonhormonal back-up method of birth control should be considered. Several cases of contraceptive failure and unscheduled bleeding have been reported in the literature with concomitant administration of antibiotics such as ampicillin and other penicillins, and tetracyclines. However, clinical pharmacology studies investigating drug interactions between combined oral contraceptives and these antibiotics have reported inconsistent results. Enterohepatic recirculation of estrogens may also be decreased by substances that reduce gut transit time.

Source: FDA prescribing information (DailyMed). Set ID: 44fbc5ae-5682-471f-a12a-955e8b4d233a. SPL document ID: ed921f2c-7961-477a-bbac-2e666d32e3ba. Label effective date: January 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.